FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129197373> ?p ?o ?g. }

• W3129197373 endingPage "428.e9" @default.
• W3129197373 startingPage "428.e1" @default.
• W3129197373 abstract "Haploidentical hematopoietic cell transplantation (HaploHCT) is an alternative treatment option for patients without a suitable 10/10 HLA matched donor. We share an updated experience at our center of using in vivo dual T-cell depletion with anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCy) in peripheral blood haploHCT and report the impact of reducing the dose of ATG from 4.5 mg/kg to 2 mg/kg on post-transplantation complications and outcomes. Ninety-five consecutive adults underwent haploHCT at our center between August 2016 and February 2020, all of whom were included in the study. Nine (9.5%) patients received myeloablative conditioning, and 86 (90.5%) patients underwent reduced-intensity haploHCT. All patients received thymoglobulin, PTCy and cyclosporine (CsA) for graft-versus-host disease (GVHD) prophylaxis: Sixty (63.2%) patients received 4.5 mg/kg, and 35 (36.8%) patients received 2 mg/kg of ATG. Clinical information was collected retrospectively and updated in June 2020. The median age was 57 (18-73), and acute myeloid leukemia was the most prevalent diagnosis (58.9%). The day 100 cumulative incidence of grade II-IV and grade III-IV aGVHD, and 1-year moderate/severe cGVHD were 22.3%, 11.1%, and 20.2%, respectively. Those patients who received 2 mg/kg of ATG had higher incidence of grade III-IV aGVHD (23.9% vs 3.5%, P = .006) and comparable moderate/severe cGVHD (1-year 20.6% vs 19.8%, P = .824) than those patients who received 4.5 mg/kg. Overall, the 18-month overall survival (OS), relapse-free survival (RFS), and non-relapse mortality (NRM) were 43.8%, 38.4%, and 40.2%, respectively. The reduction of the ATG dose did not have a significant impact in OS (hazard ratio [HR] 1.06, P = .847), RFS (HR 0.984, P = .955), and in NRM (HR 1.38; P = .348). The reduction of the ATG resulted in a negative impact on aGVHD without conferring any benefit in OS, RFS, and NRM. Consequently, the ATG dose used at our institution in combination with PTCy and CsA for haploHCT continues to be 4.5 mg/kg." @default.
• W3129197373 created "2021-03-01" @default.
• W3129197373 creator A5014346242 @default.
• W3129197373 creator A5017586094 @default.
• W3129197373 creator A5023769321 @default.
• W3129197373 creator A5035950254 @default.
• W3129197373 creator A5038048073 @default.
• W3129197373 creator A5040159118 @default.
• W3129197373 creator A5051261755 @default.
• W3129197373 creator A5057593975 @default.
• W3129197373 creator A5071646305 @default.
• W3129197373 creator A5072952978 @default.
• W3129197373 creator A5073179735 @default.
• W3129197373 creator A5080055664 @default.
• W3129197373 creator A5084708084 @default.
• W3129197373 date "2021-05-01" @default.
• W3129197373 modified "2023-10-14" @default.
• W3129197373 title "Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation" @default.
• W3129197373 cites W1143926460 @default.
• W3129197373 cites W1951884638 @default.
• W3129197373 cites W1978164777 @default.
• W3129197373 cites W2001175629 @default.
• W3129197373 cites W2033205664 @default.
• W3129197373 cites W2039334806 @default.
• W3129197373 cites W2041194455 @default.
• W3129197373 cites W2064085613 @default.
• W3129197373 cites W2071751411 @default.
• W3129197373 cites W2080170460 @default.
• W3129197373 cites W2120119492 @default.
• W3129197373 cites W2141696179 @default.
• W3129197373 cites W2160666689 @default.
• W3129197373 cites W2292440024 @default.
• W3129197373 cites W2379365975 @default.
• W3129197373 cites W2553604175 @default.
• W3129197373 cites W2629910568 @default.
• W3129197373 cites W2681369214 @default.
• W3129197373 cites W2771298034 @default.
• W3129197373 cites W2771598353 @default.
• W3129197373 cites W2783537323 @default.
• W3129197373 cites W2884698784 @default.
• W3129197373 cites W2919180304 @default.
• W3129197373 cites W2972226667 @default.
• W3129197373 cites W2975840066 @default.
• W3129197373 cites W2990164885 @default.
• W3129197373 cites W3004720827 @default.
• W3129197373 cites W3049422201 @default.
• W3129197373 cites W3080295591 @default.
• W3129197373 cites W3093156820 @default.
• W3129197373 cites W3097498722 @default.
• W3129197373 doi "https://doi.org/10.1016/j.jtct.2021.02.007" @default.
• W3129197373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33965185" @default.
• W3129197373 hasPublicationYear "2021" @default.
• W3129197373 type Work @default.
• W3129197373 sameAs 3129197373 @default.
• W3129197373 citedByCount "8" @default.
• W3129197373 countsByYear W31291973732021 @default.
• W3129197373 countsByYear W31291973732022 @default.
• W3129197373 countsByYear W31291973732023 @default.
• W3129197373 crossrefType "journal-article" @default.
• W3129197373 hasAuthorship W3129197373A5014346242 @default.
• W3129197373 hasAuthorship W3129197373A5017586094 @default.
• W3129197373 hasAuthorship W3129197373A5023769321 @default.
• W3129197373 hasAuthorship W3129197373A5035950254 @default.
• W3129197373 hasAuthorship W3129197373A5038048073 @default.
• W3129197373 hasAuthorship W3129197373A5040159118 @default.
• W3129197373 hasAuthorship W3129197373A5051261755 @default.
• W3129197373 hasAuthorship W3129197373A5057593975 @default.
• W3129197373 hasAuthorship W3129197373A5071646305 @default.
• W3129197373 hasAuthorship W3129197373A5072952978 @default.
• W3129197373 hasAuthorship W3129197373A5073179735 @default.
• W3129197373 hasAuthorship W3129197373A5080055664 @default.
• W3129197373 hasAuthorship W3129197373A5084708084 @default.
• W3129197373 hasBestOaLocation W31291973731 @default.
• W3129197373 hasConcept C120665830 @default.
• W3129197373 hasConcept C121332964 @default.
• W3129197373 hasConcept C126322002 @default.
• W3129197373 hasConcept C141071460 @default.
• W3129197373 hasConcept C2776694085 @default.
• W3129197373 hasConcept C2776755627 @default.
• W3129197373 hasConcept C2777408962 @default.
• W3129197373 hasConcept C2777630719 @default.
• W3129197373 hasConcept C2779972918 @default.
• W3129197373 hasConcept C2780882860 @default.
• W3129197373 hasConcept C2909675724 @default.
• W3129197373 hasConcept C2911091166 @default.
• W3129197373 hasConcept C61511704 @default.
• W3129197373 hasConcept C71924100 @default.
• W3129197373 hasConcept C88879693 @default.
• W3129197373 hasConcept C90924648 @default.
• W3129197373 hasConceptScore W3129197373C120665830 @default.
• W3129197373 hasConceptScore W3129197373C121332964 @default.
• W3129197373 hasConceptScore W3129197373C126322002 @default.
• W3129197373 hasConceptScore W3129197373C141071460 @default.
• W3129197373 hasConceptScore W3129197373C2776694085 @default.
• W3129197373 hasConceptScore W3129197373C2776755627 @default.
• W3129197373 hasConceptScore W3129197373C2777408962 @default.
• W3129197373 hasConceptScore W3129197373C2777630719 @default.
• W3129197373 hasConceptScore W3129197373C2779972918 @default.

• next